Clinical trials: Migraine, Acute
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Normobaric Oxygen (NBO) Therapy in Acute Migraine
This is a pilot study investigating the therapeutic potential of breathing 100% oxygen in acute migraine headache.
- Trial name
- NCT01542307
- Testing
- Oxygen, Room air
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SAMURAI (NCT02439320)
- Testing
- Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 92 sites in United States
- Volunteers
- 2,231 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- SUMMIT (NCT04940390)
- Testing
- Dihydroergotamine
- Where
- 127 sites in United States
- Volunteers
- 1,591 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Acute Migraine
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine.
- Trial name
- NCT04089761
- Testing
- Nerivio
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theranica
Acute Migraine
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
- Trial name
- NCT05371652
- Testing
- Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Where
- 26 sites in China
- Volunteers
- 241 people
- Sponsor
- Pfizer
Cyclic Vomiting Syndrome
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
- Trial name
- NCT04645953
- Testing
- 3mg AZ-010, 1mg AZ010
- Where
- 18 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine Disorders
A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents
Migraine is a neurological disease characterized by severe and recurrent headaches. Children and adolescents with migraine often present to the emergency department (ED) with acute attacks, where migraine accounts for up to ~30%…
- Trial name
- NCT05102591
- Testing
- Ketorolac, Metoclopramide, Active Remote Electrical Neuromodulation Device
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary
Acute Migraine
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
- Trial name
- NCT04153409
- Testing
- LAT8881
- Where
- 3 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Lateral Pharma Pty Ltd
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine
This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity.
- Trial name
- ADAM (NCT03282227)
- Testing
- M207 Microneedle System
- Where
- 31 sites in United States
- Volunteers
- 342 people
- Sponsor
- Zosano Pharma Corporation
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.
- Trial name
- NCT00516737
- Testing
- Comparator: rizatriptan benzoate
- Volunteers
- 207 people
- Sponsor
- Organon and Co
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine
Dexamethasone for Migraine - Dose Comparison
Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
- Trial name
- NCT04112823
- Testing
- Dexamethasone 4mg, Dexamethasone 16mg
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Montefiore Medical Center
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica